Pfizer's Coronavirus Vaccine Data Is Better Than Meets the Eye
As of Tuesday, there have been more than 50.9 million confirmed cases of the novel coronavirus worldwide, and 1.26 million deaths. In the U.S. alone, researchers estimate that the total economic impact (healthcare costs, lost productivity from lockdowns and quarantines, travel disruptions, etc.) of the rampant spread of the SARS-CoV-2 virus will likely reach $16 trillion. And the pain won't end in 2020 -- the Congressional Budget Office projects a total of $7.6 trillion in lost output over the next decade, meaning either more Treasury offerings, austerity measures, higher taxes, or all three will be needed to make up for the budget deficit.
Luckily, Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) have developed a COVID-19 vaccine candidate (BNT162b2) to help put an end to the pandemic. BNT162b2 is currently the only experimental vaccine that has demonstrated efficacy in large-scale studies, and it could become the first candidate authorized for use by regulatory agencies around the world.
But just how good is the vaccine data, and why does it matter to current or prospective investors in either company?
Source Fool.com
